hCAP18 Levels and Vitamin D Deficiency in Chronic Kidney Disease
Not Applicable
Withdrawn
- Conditions
- Chronic Kidney DiseaseVitamin D Deficiency
- Interventions
- Registration Number
- NCT01026363
- Lead Sponsor
- Massachusetts General Hospital
- Brief Summary
The human immune system produces a protein called hCAP18 (also known as LL-37 or cathelicidin). This protein is believed to help the body to fight infections. Studies suggest that vitamin D may important in the production of hCAP18. This study is designed to test the ability of two different forms of vitamin D to affect levels of hCAP18. Vitamin D and hCAP18 levels will be measured during an initial visit. Individuals who are vitamin D deficient will be randomly assigned to receive one of two forms of vitamin D for two weeks. After this, follow-up levels will be measured.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- Age 18-80
- Chronic Kidney Disease stage 3-4 (estimated glomerular filtration rate 15-60 ml/min)
Exclusion Criteria
- 6 month history of hypercalcemia, hyperphosphatemia, or nephrolithiasis
- use of active vitamin D analog within 30 days
- functioning renal transplant
- Symptoms of active infection
- Granulomatous disorders
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description ergocalciferol Ergocalciferol Ergocalciferol intervention arm calcitriol Calcitriol calcitriol intervention arm
- Primary Outcome Measures
Name Time Method hCAP18 levels 2 weeks
- Secondary Outcome Measures
Name Time Method 25-hydroxyvitamin D 2 weeks Parathyroid hormone 2 weeks calcium 2 weeks T-cell subsets 2 weeks Measures of different types of T-cells
phosphorus 2 weeks 1,25-dihydroxyvitamin D 2 weeks
Trial Locations
- Locations (1)
Massachusetts Institute of Technology
🇺🇸Cambridge, Massachusetts, United States